NVO Novo Nordisk A/S Common Stock

41.86
+0.19  (0%)
Previous Close 41.67
Open 41.58
Price To book 17.60
Market Cap 104.47B
Shares 2,495,800,000
Volume 1,136,164
Short Ratio 0.69
Av. Daily Volume 2,337,300

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing resubmission noted March 29, 2017 in response to CRL issued October 2016. Estimated latest possible PDUFA date - September 29, 2017 using 6-month timeline. Waiting for official date from company.
Fast-acting insulin aspart
Type 1 and type 2 diabetes
Phase 3 completed.
Somapacitan (NN8640)
Adult Growth Hormone Deficiency (AGHD)
Phase 3 trials ongoing as of November 2016.
Oral semaglutide (NN9924)
Type 2 diabetes
Phase 2 data due 3Q 2017.
Semaglutide (NN9536)
Obesity
Phase 2 ongoing.
Anti-IL 21 GLP-1 T1D (NNc)
Type 1 diabetes
NDA filed December 5, 2016. PDUFA estimate December 5, 2017.
Semaglutide
Type 2 diabetes
BLA filing announced May 16, 2016. PDUFA estimate May 16, 2017. Advisory Committee Meeting April 4, 2017. Still waiting for decision. The company's official guidance is for a decision during 2Q 2017. However, BPC has used a 12-month timeframe from the date of its BLA filing announcement.
Nonacog beta pegol
haemophilia B

Latest News

  1. 5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio
  2. AstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk
  3. Novo Nordisk Diabetes Lead Unscathed Following AstraZeneca Trial
  4. Nevada Senate Passes Bill to Force Diabetes Drug Manufacturers to Disclose Pricing Practices
  5. The 3 Best Obesity-Drug Stocks to Buy in 2017
  6. Novelion CEO quits Novo Nordisk board due to NASH conflict
  7. The prices for life-saving diabetes medications have increased again
  8. Novo Nordisk Sees More Competition in U.S. Drug Prices
  9. Novo Nordisk CEO: Most growth coming from organic pipelin...
  10. Novo Nordisk A/S Jumps Over Its Lowered Bar
  11. Novo Nordisk (NVO) Beats on Q1 Earnings, Revenues Down Y/Y
  12. [$$] Novo Nordisk Struggles to Raise Prices
  13. [$$] Novo Nordisk Narrows Guidance as Earnings Beat Forecasts
  14. European stocks end lower, retreating from 20-month high ahead of Fed
  15. Novo Nordisk Launches Xultophy® 100/3.6 (insulin degludec and liraglutide injection) in the United States
  16. Novo Nordisk Hits 2017 High After Q1 Profit Beat, Full-Year Guidance Boost
  17. Drugmaker Novo Nordisk nudges up full-year profit outlook after Q1 beat
  18. Novo Nordisk beats 1Q profit forecasts
  19. Novo's Legal Challenges Mount as States Query Insulin Prices
  20. Drugmaker Novo Nordisk beats Q1 operating profit forecast, nudges up FY outlook range